Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin conventional versus pharmacokinetically guided dosing trial
ACTRN12608000573358Phase 4Completed
- Sponsor
- School of Pharmacy
- Start
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of enoxaparin in acute coronary syndrome (ACS), deep vein thrombosis (DVT), Atrial fibrillation (AFib) and 1 more (2 arms), sponsored by School of Pharmacy. Primary endpoint: Total number of patients with any bleeding event. Started Dec 2009; status: completed.
02
Drugs
enoxaparin
03
Conditions
acute coronary syndrome (ACS)deep vein thrombosis (DVT)Atrial fibrillation (AFib)pulmonary embolism (PE)
Beyond the preview
Go deeper on ACTRN12608000573358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000573358.